| | 2010 News Releases  | Date | | Title | | Sep 02, 2010 |  | Blood Publication Shows MLN4924 Preclinical Activity in Lymphoma | | Jun 07, 2010 | | New Clinical Data on Millennium Solid Tumor Compounds Presented at American Society of Clinical Oncology | | Jun 06, 2010 | | Oral Presentations Showcase Impressive Results of Velcade® (bortezomib) Based Therapy in Multiple Myeloma | | Jun 05, 2010 | | Seattle Genetics and Millennium Report Positive Data on Retreatment with Brentuximab Vedotin (SGN-35) in Lymphoma | | Jun 04, 2010 | | Velcade® (Bortezomib) Data in Relapsed or Refractory Amyloidosis Presented at American Society of Clinical Oncology Annual Meeting | | May 24, 2010 | | Seattle Genetics and Millennium Complete Enrollment of Brentuximab Vedotin (SGN-35) Phase II ALCL Trial | | May 20, 2010 | | Millennium Announces VELCADE Presentations and First Data in Solid Tumors for Pipeline Molecules at American Society of Clinical Oncology Annual Meeting | | May 10, 2010 | | Takeda to Co-promote VELCADE® (bortezomib) for Injection in Japan | | Apr 29, 2010 | | Journal of Clinical Oncology Publishes Data on Overall Survival Benefit of Velcade® (Bortezomib) for Injection in Patients with Previously Untreated Multiple Myeloma | | Apr 08, 2010 | | Seattle Genetics, Takeda and Millennium Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin Lymphoma | | Mar 08, 2010 | | Millennium Announces First Clinical Data For TAK-700 Prostate Molecule At ASCO GU | | Feb 03, 2010 | | Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma | | Jan 15, 2010 | | Molecular Cell Publishes Data on A Novel Form of Enzyme Inhibition of A Protein Homeostasis Target | | Jan 04, 2010 | | FDA Approves Addition of Sustained Overall Survival Benefit to Label for Velcade® (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma |
|
|
|
|
|
